002241:SZSEGoertek Inc. Analysis
Data as of 2026-03-07 - not real-time
CN¥25.36
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Goertek Inc. (002241.SZ) is trading at ¥25.36, comfortably below its 20‑day SMA of ¥26.21 and the 50‑day SMA of ¥27.84. The 14‑day RSI sits at 37.4, indicating limited buying momentum but not yet oversold territory. A bearish MACD histogram (‑0.06) reinforces the short‑term downside bias. The stock is perched near a technical support level of ¥24.70, with resistance around ¥27.20. Volume has remained stable, while 30‑day price volatility is elevated at roughly 28%, suggesting price swings could be sizable. Market sentiment is bullish, as reflected by a fear‑greed index of 68.8 (“Greed”).
Fundamentally, revenue grew 4.4% YoY to ¥99.4 bn, yet margins remain thin (gross 11.9%, net 2.9%). The trailing PE of 30.2 is below the industry average of 36.2, but a discounted cash‑flow model values the company at only ¥8.02, implying the market price is materially overvalued. The balance sheet shows net cash of ¥0.88 bn and a debt‑to‑equity of 59%, a manageable leverage profile for a cash‑rich tech firm. Dividend yield stands at 1.58% with a payout ratio of 30%, supporting the view that the dividend is sustainable. Analyst consensus is a “Buy” with a median target of ¥35.8, indicating roughly 35% upside potential. Given the mixed technical weakness, overvaluation relative to DCF, and solid cash flow, we rate the stock as a medium‑term buy but advise caution on short‑term entries.
Fundamentally, revenue grew 4.4% YoY to ¥99.4 bn, yet margins remain thin (gross 11.9%, net 2.9%). The trailing PE of 30.2 is below the industry average of 36.2, but a discounted cash‑flow model values the company at only ¥8.02, implying the market price is materially overvalued. The balance sheet shows net cash of ¥0.88 bn and a debt‑to‑equity of 59%, a manageable leverage profile for a cash‑rich tech firm. Dividend yield stands at 1.58% with a payout ratio of 30%, supporting the view that the dividend is sustainable. Analyst consensus is a “Buy” with a median target of ¥35.8, indicating roughly 35% upside potential. Given the mixed technical weakness, overvaluation relative to DCF, and solid cash flow, we rate the stock as a medium‑term buy but advise caution on short‑term entries.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price below key moving averages
- Bearish MACD signal
- Proximity to technical support
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Analyst consensus buy with 35% upside
- Improving forward PE and EPS guidance
- Solid cash position and sustainable dividend
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- DCF indicates significant overvaluation
- Modest revenue growth and thin margins
- Manageable leverage and net cash
Key Metrics & Analysis
Financial Health
Revenue Growth4.40%
Profit Margin2.92%
P/E Ratio30.2
ROE8.17%
ROA2.05%
Debt/Equity59.11
P/B Ratio2.5
Op. Cash FlowCN¥5.0B
Free Cash FlowCN¥1.7B
Industry P/E36.2
Technical Analysis
TrendNeutral
RSI37.4
SupportCN¥24.70
ResistanceCN¥27.20
MA 20CN¥26.21
MA 50CN¥27.84
MA 200CN¥27.68
MACDBearish
VolumeStable
Fear & Greed Index68.77
Valuation
Fair ValueCN¥8.02
Target PriceCN¥34.30
Upside/Downside35.25%
GradeOvervalued
TypeBlend
Dividend Yield1.58%
Risk Assessment
Beta0.49
Volatility27.67%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.